Health In Tech, Inc. (HIT): Nasdaq/NYSE listing notice — Health In Tech receives Nasdaq bid-price deficiency notice; 180 days to cure

Health In Tech, Inc.

On April 28, 2025, Nasdaq notified Health In Tech that its Class A common stock (HIT) failed to maintain minimum $1.00 bid price for 30 consecutive business days.
Company has until October 27, 2025 to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not cured, the company may seek an additional 180-day extension by meeting other listing standards and providing a plan (e.g., reverse stock split).
No immediate effect on listing or trading; stock continues to trade on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Health In Tech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 28, 2025, Health In Tech, Inc. (the “Company”) received a letter (the “Nasdaq Staff Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the closing bid price for the Company’s Class A common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 27, 2025, to regain compliance. The letter stat

View on SEC.gov

Browse all listing & compliance notices →

Health In Tech, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-036829

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.